PD-L1 agents in the treatment of NSCLC Initial Results of the Ongoing MYSTIC Trial in Stage IV Lung Cancer David Gandara, MD, discusses the positioning of Cyramza post platinum therapy in NSCLC patients
David R. Gandara, MD, on what will change about patient selection as a result of Keynote 42 Dr. Gandara on Measuring TMB in NSCLC
In his second visit to the Lung Cancer Living Room, Dr. David Gandara of UC Davis Comprehensive Cancer Center, discusses Dr. Gandara on Practice-Changing Studies in Lung Cancer
Lung Cancer Voices Podcast: Advances in Lung Cancer, Achievements, Hopes and Challenges Dr. David Gandara Describes Exciting New Lung Cancer Research
Dr. Gandara Discusses the Future of Clinical Trial Designs Dr. Gandara, Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center, on what will
David R. Gandara, MD, on whether Keynote 189 impacted view of PDL-1 expression and patient selection Rapid Response Living Room - Lung Cancer is Not Taking a Back Seat, Care Must Go On - 05/05/20
Rapid Response Living Room: Lung Cancer is Not Taking a Backseat - Dr. David Gandara - May 5, 2020 During the ASCO meeting, David Gandara, M.D., Professor of Medicine, Director, Thoracic Oncology Program, UC Davis David Gandara, MD, professor, Division of Hematology/Oncology, University of California Davis Comprehensive Cancer Center,
Dr. David Gandara on Patient Selection for Molecular Testing in Lung Cancer David Gandara, MD - Professor at UC Davis Comprehensive Cancer Living Room Highlights: Determining Whether to Use a Solid or Liquid Biopsy in the Time of COVID
Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing David R. Gandara's research works | University of California, Davis David Gandara, MD, discusses considerations when choosing between immunotherapy and chemotherapy
Dr. Gandara Discusses the OAK Trial for Lung Cancer In today's episode, we had the pleasure of speaking with David R. Gandara, MD, about biomarker testing in lung cancer. Dr Gandara is the chief David R. Gandara, MD. Adjunct Clinical Professor, Translational and Clinical Research Program University of Hawai'i Cancer Center
David Gandara | UC Davis Profiles Dr. David Gandara Discusses Multiplexing Molecular Tests for NSCLC
Dr. Gandara on Online Treatment Decision Tool for Lung Cancer David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, University of California Davis
Dr. Gandara on Recent Advancements in Field of Lung Cancer David R. Gandara, M.D. for UC Davis Health
An evening with David R. Gandara, M.D. from UC Davis Cancer Center. Diagnostic Advances Shape Treatment Decisions in Lung Cancer David R. Gandara, MD, shares the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC
David Gandara (@drgandara) / Posts / X Dr. David Gandara Spotlights the Giants of Cancer Care Dr. Gandara on How Lung-MAP Trial is Optimal for Patient Care
Topic: Lung Cancer is Not Taking a Backseat, Neither Are We – Care Must Go On Speaker: David R. Gandara, MD - Professor of David R. Gandara, MD, Director, Thoracic Oncology Program, University of California, Davis Comprehensive Cancer Center,
David R. Gandara's 921 research works with 57610 citations, including: A Plasma Proteomics Test Predicts Immunotherapy Benefit in NSCLC Independent of Acquired resistance to targeted therapies against oncogene-driven Increasing treatment options for NSCLC
Dr. Gandara on Treatment Options for Squamous Cell NSCLC David Gandara, MD, current thinking regarding testing for PD-L1 biomarker in NSCLC patients Dr. Gandara, Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center, discusses
David Gandara, MD,, discusses PD-L1 expression and selecting the appropriate agent in NSCLC patients In this week's Rapid Response episode of The Lung Cancer Living Room, our host Danielle Hicks and guest, Dr. David Gandara Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). JCO Precis Oncol. 2023 09; 7:e2300218. Vaidya R, Unger JM, Qian L,
David R. Gandara, MD, professor of Medicine, University of California Davis Comprehensive Cancer Center, discusses the initial 3rd Annual Hawaii Lung A Multidisciplinary Case-Based Conference David R. Gandara, MD, Professor of Medicine, Division of Hematology and Oncology, Director, Thoracic Oncology Program,
Dr. Gandara on the MYSTIC Trial for Lung Cancer David R. Gandara, MD, invites you to the 23rd Annual International Lung Cancer Congress® 7/28-7/30
David R. Gandara, MD, invites you to the 23rd Annual International Lung Cancer Congress® July 28 - July 30, 2022. Join PER® David Gandara, MD, from the University of California, Davis, CA discusses the results of the OAK trial (NCT02008227) and how David R. Gandara, M.D., UC Davis Comprehensive Cancer Center, discusses how diagnostic and therapeutic changes are
Topic: Lung Cancer is Not Taking a Backseat, Neither Are We – Care Must Go On Speaker: David R. Gandara, MD Professor of Prof. David Gandara speaking about the IASLC Consensus Statement on Liquid Biopsy Dr. Gandara, Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center,
Dr. David Gandara is a clinician-scientist and lung cancer specialist internationally recognized for his expertise in thoracic cancers (lung cancer), cancer Roy S. Herbst, MD, PhD, Chief of Medical Oncology, Yale Comprehensive Cancer Center, describes the 12th International Lung
Dr. Gandara on the Utility of TMB in NSCLC Living Room Highlights: Second Opinion Appointments Using Telehealth Entrevista con los expertos Dr. Bartomeu Massuti- Dr. David R. Gandara
Dr. Gandara on the Heat Shock Protein 90 Inhibitor Ganetespib Dr. Gandara, Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center on whether
Dr. Gandara Discusses Third-Generation EGFR TKIs David Gandara (@drgandara) - Posts - Medical Oncologist & clinical-translational researcher in lung cancer. Co-Director-Center for Experi. David Gandara, MD, discusses pembrolizumab vs docetaxel for previously treated NSCLC patients
On our first podcast, Dr. Paul Wheatley-Price, Medical Oncologist at The Ottawa Hospital and President of Lung Cancer Canada, Dr. Gandara, Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center, shares the
Dr. Gandara on the Impact of Immunotherapy on the Tumor Microenvironment in Lung Cancer David R. Gandara, MD - ILCN.org (ILCN/WCLC) Dr. David Gandara on Thymidylate Synthase Expression in ALK-Positive Non-Small Cell Lung Cancer
David Gandara, MD, Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center, tell Dr. Gandara on Strategies for Overcoming KRAS Mutations in Lung Cancer
(Edited version) In this week's Rapid Response episode of The Lung Cancer Living Room, our host Danielle Hicks and guest, Dr. Dr. David R. Gandara, Editor-in-Chief of Clinical Lung Cancer, had the honor of receiving the third annual Addario Lectureship. Award
Dr. David R. Gandara Receives Third Annual Addario Lectureship David R. Gandara, MD, on continuing pemextrexed maintenance
David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive David R. Gandara, MD, discusses exciting new developments in lung cancer here at ASCO 2018 International Society of Liquid Biopsy 2021 Virtual Meeting
David R. Gandara, MD, discusses the impact of immunotherapy on the tumor microenvironment in lung cancer. Website: Dr. Gandara is Professor and Director of Thoracic Oncology at UC Davis Comprehensive Cancer Center, Sacramento, US. He is former President of IASLC.
David R. Gandara, MD, discusses drug sequencing as a result of Keynote 189 and 42 results David Gandara, MD, UC Davis Comprehensive Cancer Center, Sacramento, CA, gives an overview of the International Society of
David Gandara, MD from the University of California, Davis, CA discusses the recent change in the treatment landscape of Lung Cancer Living Room - 05-05-20 THE LUNG CANCER LIVING ROOM™ - PERSONALIZING YOUR CARE - DR. DAVID GANDARA - FEB. 19, 2013
Authors. David R Gandara , Tianhong Li , Primo N Lara , Karen Kelly , Jonathan W Riess , Mary W Redman , Philip C Mack. Affiliations. 1 Dr. Herbst on the International Lung Cancer Congress Lung Cancer Living Room pRIME Special 01/23/17
David Gandara, MD, talks about the potential impact of immunotherapy in 1st line NSCLC Dr. Gandara is Professor Emeritus at the University of California Davis Comprehensive Cancer Center (UCDCCC) where he is Director of Thoracic Oncology. David Gandara, M.D., Professor of Medicine, Director, Thoracic Oncology Program, UC Davis Comprehensive Cancer Center,
Dr. Gandara Discusses Clinical Implications of the FLAURA Study in NSCLC